Results 81 to 90 of about 1,866 (169)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1831-1839, November 2026.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review

Bimekizumab is the most recent interleukin (IL)-17 inhibitors (IL-17i) approved for plaque psoriasis in adult patients. Despite biologic switching being common in routine clinical practice, evidence remains sparse regarding switching within class from ...
Sood, Siddhartha
core   +1 more source

Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year

Dermatology and Therapy
Introduction Individuals with psoriatic arthritis (PsA) and plaque-type psoriasis and nail involvement have more severe disease and worse quality of life than those without. Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (
Diamant Thaçi, Akihiko Asahina, Wolf-Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Heather Edens, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola   +10 more
doaj   +1 more source

Single-Injection Options for Administering a 320 mg Dose of Bimekizumab: 2 mL Safety Syringe and Auto-injector

Dermatology and Therapy
Introduction Bimekizumab has a favourable safety profile and has demonstrated rapid and superior efficacy, compared with placebo, adalimumab, ustekinumab, and secukinumab, in treating psoriasis.
Michael Sebastian, Jerry Bagel, Bengt Hoepken, Bertram Knapp, Ceyhun Bicer, Merran MacPherson, Richard G. Langley   +6 more
doaj   +1 more source

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis – A Comprehensive Literature Review

Psoriasis
Psoriasis is a chronic inflammatory immune‐mediated disease that affects 1–3% of the worldwide population. It is now known that interleukin IL-17F and IL-17A have a role in the pathophysiology of immune-mediated inflammatory disorders, such as psoriasis.
Sukainah Ahmed Al Alshaikh, ZM Almarhoon, Hisham Momattin, Mahdi Aleid, Z. Almousa, A. K. Alqaisum, F. Mobarki, S. Almakki, Hamzah Alturfi, K. Almajed   +9 more
semanticscholar   +1 more source

Evaluating the Efficacy of Bimekizumab across the Different Sensitive Areas in Moderate-to-Severe Psoriasis: A 52-week Italian Multicenter Real-Life Lazio Experience

Dermatology Practical & Conceptual
Introduction Psoriasis significantly impacts a patient’s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors.
A. Dattola, N. Bernardini, E. Campione, E. Amore, Simone Amato, G. Caldarola, C. De Simone, Domenico Giordano, G. Moretta, V. Panasiti, G. Pagnanelli, Vincenzo Roberti, R. G. Shumak, Nevena Skorza, E. Tolino, Paola Tribuzi, S. Zanframundo, L. Bianchi, S. Persechino, C. Potenza, G. Pellacani, K. Peris, A. Richetta   +22 more
semanticscholar   +1 more source

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and ...
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates   +13 more
doaj   +1 more source

Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: a systematic review and meta-analysis

Bimekizumab, a humanized monoclonal IgG1 antibody targeting both interleukin (IL)-17A and IL-17F, could be effective for treating Psoriatic arthritis (PsA).
Jia-Jing Cao (18421142), Liu Yang (23752), Ting-Yu Cao (18421133), He-Yi Zhang (18420228), Yue-Hong Huo (18421145), Qin-Yi Su (14188151), Zhuo-Chen Han (18421139), Hai-Ying Dang (18421136), Ting Cheng (1692172), Sheng-Xiao Zhang (8832449)   +9 more
core   +1 more source

Rapid response on facial psoriasis to bimekizumab: case series

Drugs in Context
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact.
Nicoletta Bernardini, Annunziata Dattola, Giacomo Caldarola, Diego Orsini, Chiara Assorgi, Alessandra D’Amore, Giulia Maretti, Antonio Giovanni Richetta, Ersilia Tolino, Nevena Skroza, Concetta Potenza   +10 more
doaj   +1 more source

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons

Rheumatology and Therapy
Introduction Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A and was approved to treat patients with active psoriatic arthritis (PsA) in the European Union in 2023.
Jorge Mestre-Ferrandiz, Victoria Navarro-Compán, Yoana Ivanova-Markova, Almudena González-Domínguez, Stefano Maratia   +4 more
doaj   +1 more source